A business in context

KRSA research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-11-17 · 7996 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 10-Q · Quarterly report

    Report date 2026-09-30 · 0001193125-26-448636

  2. 8-K · Current report

    Report date 2026-11-05 · 0001193125-26-448535 · Items 2.02,9.01

  3. DEF 14A · Proxy statement

    Report date 2026-11-13 · 0001193125-26-422893

  4. 8-K · Current report

    Report date 2026-09-08 · 0001193125-26-389318 · Items 1.01,2.01,2.02,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01

  5. 4 · Ownership change

    Report date 2026-09-09 · 0001193125-26-388146

  6. 4 · Ownership change

    Report date 2026-09-09 · 0001193125-26-388144

  7. 4 · Ownership change

    Report date 2026-09-09 · 0001193125-26-388142

  8. 4 · Ownership change

    Report date 2026-09-09 · 0001193125-26-388136

  9. 8-K · Current report

    Report date 2026-08-26 · 0001193125-26-369426 · Items 5.07,8.01,9.01

  10. 8-K · Current report

    Report date 2026-08-25 · 0001193125-26-365150 · Items 8.01

  11. 4 · Ownership change

    Report date 2026-08-14 · 0001193125-26-355721

  12. 4 · Ownership change

    Report date 2026-08-14 · 0001193125-26-355707

  13. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-332842

  14. 4 · Ownership change

    Report date 2026-07-16 · 0001193125-26-309048

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-219478

  16. 10-K/A · Annual report

    Report date 2025-12-31 · 0001193125-26-194204

  17. 8-K · Current report

    Report date 2026-04-01 · 0001193125-26-137909 · Items 1.01,5.01,5.02,7.01,9.01

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-132193

  19. 8-K · Current report

    Report date 2026-02-17 · 0001193125-26-053035 · Items 7.01,9.01

  20. 8-K · Current report

    Report date 2026-01-03 · 0001193125-26-003509 · Items 1.01,7.01,9.01

  21. 8-K · Current report

    Report date 2025-12-01 · 0001193125-25-304067 · Items 8.01

  22. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-277749

  23. 10-K/A · Annual report

    Report date 2024-12-31 · 0001193125-25-277621

  24. 8-K · Current report

    Report date 2025-09-19 · 0001193125-25-213332 · Items 1.01,7.01,9.01

  25. 4 · Ownership change

    Report date 2025-08-07 · 0000950170-25-106532

  26. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-103123

  27. 8-K · Current report

    Report date 2025-06-16 · 0001193125-25-142765 · Items 5.07,9.01

  28. 8-K · Current report

    Report date 2025-05-07 · 0001193125-25-115089 · Items 1.01,9.01

  29. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-064493

  30. DEF 14A · Proxy statement

    Report date 2025-06-16 · 0001140361-25-016370

  31. 8-K · Current report

    Report date 2025-03-21 · 0001193125-25-062612 · Items 1.01,3.02,9.01

  32. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-032037

  33. 8-K · Current report

    Report date 2024-12-13 · 0001193125-24-280125 · Items 1.01,7.01,9.01

  34. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-127116

  35. 8-K · Current report

    Report date 2024-08-07 · 0001193125-24-195410 · Items 7.01,9.01

  36. 10-Q · Quarterly report

    Report date 2024-06-30 · 0000950170-24-092257

  37. SC 13G/A · Ownership disclosure

    0001193125-24-178653

  38. 8-K · Current report

    Report date 2024-06-14 · 0001193125-24-161591 · Items 5.07,9.01

  39. 10-Q · Quarterly report

    Report date 2024-03-31 · 0000950170-24-054602

  40. DEF 14A · Proxy statement

    Report date 2024-06-14 · 0001140361-24-022981

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-11-14 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 4 transaction rows4AExercise / conversion: 4 transaction rows4MTax / exercise payment: 1 transaction rows1FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

11 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-09
2026-09-10
Pernice Michelle PatriciaA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
48445.00.0
2026-09-09
2026-09-10
Shah Nimish PA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
48445.00.0
2026-09-09
2026-09-10
Fairmount Funds Management LLC; Fairmount Healthcare Co-Invest VI L.P.; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
48445.00.0
2026-09-09
2026-09-10
Gottesdiener AndrewA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
48445.00.0
2026-08-14
2026-08-18
CHICKO RHONDA M.M · Exercise / conversion
Acquired
Common Stock, no par value25000.02.36
2026-08-14
2026-08-18
CHICKO RHONDA M.M · Exercise / conversion
Disposed
Option to Purchase
Derivative security
25000.00.0
2026-08-14
2026-08-18
Graul Regina MargaretF · Tax / exercise payment
Disposed
Common Stock, no par value48629.03.79
2026-08-14
2026-08-18
Graul Regina MargaretM · Exercise / conversion
Acquired
Common Stock, no par value55849.03.3
2026-08-14
2026-08-18
Graul Regina MargaretM · Exercise / conversion
Disposed
Option to Purchase
Derivative security
55849.00.0
2026-07-16
2026-07-20
Hecht Peter MC · Conversion
Acquired
Common Stock351037.0n/a
2026-07-16
2026-07-20
Hecht Peter MC · Conversion
Disposed
Series A Convertible Preferred Stock
Derivative security
351037.0n/a

Identity & relationships

Wikidata structured data · retrieved 2026-11-14 · 1656 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001755237Korsana Biosciences, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-11-14 · 1196 checked identities; 0 unavailable records

Search names and former names
  • Cyclerion Therapeutics, Inc. · former SEC name · 2018-10-09 to 2026-08-27

Revenue in constant purchasing power

USD revenue expressed in 2026-10 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$2.00M$2.15M
2023-12-31$0$0
2022-12-31$297.0K$342.5K
2021-12-31$3.94M$4.91M
2020-12-31$2.30M$2.99M
2019-12-31$4.51M$5.95M

Bureau of Labor Statistics · retrieved 2026-11-17 · 9 selected series; gaps remain missing

Explore the CPI history ↗